Edesa Biotech, Inc.
EDSANasdaqHealthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $328,801 |
| Operating income | −$7.9M | −$7.0M | −$9.2M | −$18.4M | −$23.7M | −$6.4M |
| Net income | −$7.2M | −$6.2M | −$8.4M | −$17.5M | −$13.3M | −$6.4M |
| Total assets | $13.5M | $3.8M | $8.9M | $11.6M | $14.6M | $10.8M |
| Total liabilities | — | $1.8M | $1.8M | $2.2M | $1.5M | $1.7M |
| Equity | $12.5M | $2.0M | $7.0M | $9.4M | $13.1M | $6.6M |
| EPS (diluted) | $-1.27 | $-1.93 | $-2.93 | — | — | — |
| Shares out. | 8.3M | 3.5M | 3.2M | 19.4M | 13.5M | 10.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −57.7%
- Return on assets
- −53.1%
- Return on capital (ROCE)
- −63.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.49
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 1.0%clean
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 20-Fmissed a reporting deadline ↗Dec 31, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nijhawan PardeepOfficer — Chief Executive Officer | Jun 1, 2026 | Grant | 1,671 | $0.00 |
| Marshall PatrickDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Macdonald Sean ArthurDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Chypyha JoanDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Weiler Peter J.Officer — Chief Financial Officer | May 27, 2026 | Grant | 64,609 | $0.00 |
| Brooks Michael JOfficer — President | May 27, 2026 | Grant | 64,609 | $0.00 |
| Sistilli CarloDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Olson Charles VDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Nijhawan PardeepOfficer — Chief Executive Officer | May 27, 2026 | Grant | 96,913 | $0.00 |
| Liu Da DavidDirector | May 27, 2026 | Grant | 19,000 | $0.00 |
| Nijhawan PardeepOfficer — Chief Executive Officer | May 1, 2026 | Grant | 1,159 | $0.00 |
| Nijhawan PardeepOfficer — Chief Executive Officer | Apr 1, 2026 | Grant | 2,578 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 218,598 | 1.0 | -57.4% |
| Apr 30, 2026 | 513,538 | 1.0 | +91.9% |
| Apr 15, 2026 | 267,664 | 1.0 | -32.5% |
| Mar 31, 2026 | 396,830 | 1.0 | -34.2% |
| Mar 13, 2026 | 603,458 | 1.0 | -57.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 29, 2026
- Director / officer changeMay 15, 2026
- Results of operationsMay 14, 2026
- Other material eventFeb 24, 2026
- Results of operationsFeb 13, 2026
- Other material eventDec 12, 2025
- Results of operationsDec 12, 2025
- Other material eventOct 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Jun 1, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4OWNERSHIP DOCUMENTMay 29, 2026
- S-8May 29, 2026
- 8-KFORM 8-KMay 29, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026